NEW YORK (GenomeWeb) – Diatherix has announced a multi-year research agreement with Vanderbilt University Medical Center and the Vanderbilt Vaccine Research Program. The collaboration will center on detection of bacterial and viral infections in children and adults, the company said on Thursday.
As part of the arrangement, Huntsville, Alabama-based Diatherix will provide clinical lab services using its multiplex molecular diagnostics platform. The firm's CLIA lab received accreditation from the College of American Pathologists last month.
"In the current climate of complex infections and antimicrobial resistance, securing a microbiologic diagnosis as quickly as possible is an important aspect of patient care," said VUMC principal investigator C. Buddy Creech in a statement. "We are excited about the prospect of improving our ability to make rapid diagnoses in some of our most challenging patients, such as children with bone and joint infections, as well as those with infections of the central nervous system."
Diatherix acquired a patent for target-enriched multiplexing PCR, or TEM-PCR, from Qiagen in 2013, and the firm was itself acquired by Eurofins Scientific for $50 million in June.